secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2026-07-24T20:15:40+00:00
Accession:  0001104659-26-086651
Event type: debt
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acura receives $200K loan from AD Pharma; warns of possible shutdown without more funding by mid-August
--------------------------------------------------------------------------------

- New $200K loan from Abuse Deterrent Pharma increases principal to $10.9M, bearing 5.25% interest.
- Accrued interest ~$1.2M as of July 17, 2026; overdue amounts bear 7.5% interest.
- Without additional financing by mid-August 2026, company will scale back operations, furlough/lay off employees, or seek bankruptcy.
- Failure to secure funding could result in complete loss of shareholder value.
- Loan proceeds used for day-to-day operations; no assurance of further financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465926086651/0001104659-26-086651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465926086651/tm2621293d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-086651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer